Abbott Laboratories (ABT) to Release Earnings on Thursday

Abbott Laboratories (NYSE:ABT) is expected to be releasing its Q1 2026 results before the market opens on Thursday, April 16th. Analysts expect Abbott Laboratories to post earnings of $1.15 per share and revenue of $10.9944 billion for the quarter. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. Interested persons are encouraged to explore the company’s upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Wednesday, April 15, 2026 at 9:00 AM ET.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share (EPS) for the quarter, meeting the consensus estimate of $1.50. Abbott Laboratories had a return on equity of 17.73% and a net margin of 14.72%.The business had revenue of $11.46 billion for the quarter, compared to analyst estimates of $11.80 billion. During the same quarter in the prior year, the firm posted $1.34 earnings per share. The firm’s revenue for the quarter was up 4.4% compared to the same quarter last year. On average, analysts expect Abbott Laboratories to post $5 EPS for the current fiscal year and $6 EPS for the next fiscal year.

Abbott Laboratories Trading Up 1.8%

Shares of ABT opened at $103.70 on Thursday. The company has a quick ratio of 1.18, a current ratio of 1.58 and a debt-to-equity ratio of 0.19. Abbott Laboratories has a 12-month low of $100.88 and a 12-month high of $139.06. The firm has a market capitalization of $180.61 billion, a PE ratio of 27.88, a price-to-earnings-growth ratio of 1.64 and a beta of 0.79. The stock’s fifty day simple moving average is $109.17 and its 200-day simple moving average is $120.35.

Abbott Laboratories Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be paid a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a dividend yield of 2.4%. The ex-dividend date of this dividend is Wednesday, April 15th. Abbott Laboratories’s dividend payout ratio is 67.74%.

Insider Buying and Selling at Abbott Laboratories

In other news, VP John A. Jr. Mccoy sold 585 shares of Abbott Laboratories stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $115.58, for a total transaction of $67,614.30. Following the transaction, the vice president owned 24,628 shares in the company, valued at $2,846,504.24. The trade was a 2.32% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Daniel J. Starks acquired 10,000 shares of the business’s stock in a transaction dated Wednesday, February 4th. The shares were acquired at an average price of $108.73 per share, for a total transaction of $1,087,300.00. Following the acquisition, the director directly owned 6,738,817 shares in the company, valued at $732,711,572.41. This represents a 0.15% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have sold a total of 3,055 shares of company stock worth $353,097 over the last three months. Company insiders own 0.46% of the company’s stock.

Hedge Funds Weigh In On Abbott Laboratories

Institutional investors have recently modified their holdings of the business. Wellington Management Group LLP raised its position in Abbott Laboratories by 0.8% in the 4th quarter. Wellington Management Group LLP now owns 23,434,760 shares of the healthcare product maker’s stock valued at $2,936,141,000 after buying an additional 188,616 shares during the last quarter. Charles Schwab Investment Management Inc. raised its position in Abbott Laboratories by 0.4% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 13,189,528 shares of the healthcare product maker’s stock valued at $1,652,517,000 after buying an additional 52,191 shares during the last quarter. Amundi raised its position in Abbott Laboratories by 28.3% in the 4th quarter. Amundi now owns 8,185,642 shares of the healthcare product maker’s stock valued at $1,025,578,000 after buying an additional 1,803,975 shares during the last quarter. Raymond James Financial Inc. raised its position in Abbott Laboratories by 2.0% in the 3rd quarter. Raymond James Financial Inc. now owns 5,536,178 shares of the healthcare product maker’s stock valued at $741,515,000 after buying an additional 107,843 shares during the last quarter. Finally, California Public Employees Retirement System raised its position in Abbott Laboratories by 29.7% in the 4th quarter. California Public Employees Retirement System now owns 5,206,580 shares of the healthcare product maker’s stock valued at $652,332,000 after buying an additional 1,193,410 shares during the last quarter. Institutional investors own 75.18% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on ABT. Oppenheimer cut their price target on Abbott Laboratories from $140.00 to $132.00 and set an “outperform” rating on the stock in a research note on Friday, January 23rd. Freedom Capital raised Abbott Laboratories from a “hold” rating to a “strong-buy” rating in a research note on Thursday, January 29th. Raymond James Financial lowered their price target on Abbott Laboratories from $146.00 to $130.00 and set an “outperform” rating for the company in a research note on Friday, January 23rd. Sanford C. Bernstein lowered their price target on Abbott Laboratories from $154.00 to $125.00 and set an “outperform” rating for the company in a research note on Friday, January 23rd. Finally, Citigroup lowered their price target on Abbott Laboratories from $140.00 to $136.00 and set a “buy” rating for the company in a research note on Wednesday, March 11th. Two research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $134.58.

Key Abbott Laboratories News

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Barclays raised its price target on ABT to $144 and keeps an “overweight” view, a bullish signal that likely helped buying interest. Abbott Laboratories price target raised by Barclays
• Positive Sentiment: Coverage highlighting Abbott as a “dividend king on sale” (value/dividend investors) increases interest from income-focused buyers given its long track record of payout consistency. A Dividend King on Sale: Is Abbott Labs a Healthcare Bargain?
• Neutral Sentiment: Several sell‑side analysts remain constructive (maintaining buy/outperform ratings) but trimmed targets modestly (Evercore to $134 from $138; BTIG similar), which is mixed news — keeps analyst support but reduces implied upside. Evercore ISI and BTIG Lower Abbott (ABT) Price Targets, Maintain Positive Ratings
• Neutral Sentiment: Analysts and media note the stock’s recent underperformance versus the broader market even as it edges up intraday — an important context for short‑term momentum traders. Abbott Laboratories stock rises Wednesday, still underperforms market
• Negative Sentiment: Goldman Sachs cut its price target sharply to $121 from $140 (still a “buy”), a downgrade in expectation that can pressure sentiment and cap near‑term gains. Goldman Sachs adjusts price target on Abbott Laboratories to $121 from $140; maintains buy rating
• Negative Sentiment: Analyses flag recent share weakness (down materially over the past 1–3 months) and fading momentum; fundamental concerns include a modest revenue shortfall in the last quarter despite EPS in line and only modest FY guidance — reasons some investors remain cautious. Assessing Abbott Laboratories (ABT) Valuation After Recent Share Price Weakness

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.